Nuvig Therapeutics Appoints Julie Smith Chief Executive Officer
04 Jan 2023
Executive ChangeImmunotherapy
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nuvig Therapeutics, Inc., a biopharma company developing proprietary recombinant human therapeutics for patients with autoimmune diseases, today announced the appointment of Julie Anne Smith as Chief Executive Officer (CEO) and member of the Board of Directors. Ms. Smith has over 20 years of experience in the life science industry, with a focus on leading private and public biotech companies through development and commercialization of therapeutics for orphan diseases. Pamela Conley, Ph.D., cofounder and founding CEO of Nuvig Therapeutics, will serve as the Company’s Chief Scientific Officer.
'I look forward to working with Pam and the team to propel our development candidates into the clinic with the goal of providing new therapeutic options for autoimmune diseases without broad immunosuppression.'
“The board is very grateful to Pam for leading Nuvig from inception to this exciting inflection point, as the company enters IND-enabling activities for its lead program,” said Kenneth Harrison, Ph.D., Director of Nuvig Therapeutics and Partner at Novo Ventures. “We are excited by the dynamic leadership, vision, and experience Julie brings to the company and look forward to working closely with her to advance Nuvig’s therapies to patients.”
Nuvig’s lead program is a novel recombinant human antibody fragment engineered to induce immune modulatory mechanisms that restore immune homeostasis and control inflammation in autoimmune diseases. Nuvig is extending this technology to build a pipeline of differentiated protein therapeutics that can be used in the context of varied but well-defined inflammatory and autoimmune diseases.
“I’m delighted to join Nuvig at this pivotal time as the team has received strong investor support and rapidly advanced its novel technology to the IND-enabling stage,” said Ms. Smith. “I look forward to working with Pam and the team to propel our development candidates into the clinic with the goal of providing new therapeutic options for autoimmune diseases without broad immunosuppression.”
Prior to Nuvig, Ms. Smith served as President and CEO of ESCAPE Bio, a biotech company developing precisely targeted therapies for genetic forms of neurodegeneration. She previously served as President and CEO of Raptor Pharmaceuticals, which developed and commercialized therapies for the orphan disease nephropathic cystinosis and chronic pulmonary infections before its acquisition by Horizon Pharmaceuticals. Ms. Smith also served as Chief Commercial Officer of Enobia Pharmaceuticals until it was acquired by Alexion Pharmaceuticals. Earlier in her career, she held roles at Jazz Pharmaceuticals, Genzyme, Novazyme, and Bristol-Myers Squibb. Ms. Smith serves as a director on the Boards of Exelixis (Nasdaq: EXEL) and Stoke Therapeutics (Nasdaq: STOK). Ms. Smith obtained her B.S. in biology from Cornell University.
About Nuvig Therapeutics
Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases. For more info, visit www.nuvigtherapeutics.com.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.